SGLT-2 Inhibitors Prevent Some Heart Failure Hospitalizations

Patient-level meta-analysis demonstrates benefit over time, regardless of ejection fraction or diabetes status.

Large randomized trials have shown that some sodium–glucose cotransporter-2 (SGLT-2) inhibitors — specifically dapagliflozin and empagliflozin — improve relevant outcomes (e.g., first hospitalization, mortality) in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status (NEJM JW Gen Med Jan 1 2021). In a new patient-level meta-analysis, researchers identified eight randomized trials (with >15,000 patients) to assess the effects of SGLT-2 inhibitors (i.e., canagliflozin, dapagliflozin, empagliflozin, or sotagliflozin) in patients with HFrEF or heart failure with preserved ejection fraction (HFpEF) and with or without diabetes.

SGLT-2 inhibitors significantly lowered risk for heart failure–related hosp…

Reviewing Author

Daniel D. Dressler, MD, MSc, MHM, FACP

Disclosures

RoyaltiesMcGraw-Hill; Elsevier

Editorial BoardsMedical Clinics of North America; Caribbean Medical Journal International Advisory Panel (2021–2026)

Daniel D. Dressler, MD, MSc, MHM, FACP

Disclosures

RoyaltiesMcGraw-Hill; Elsevier

Editorial BoardsMedical Clinics of North America; Caribbean Medical Journal International Advisory Panel (2021–2026)

SGLT-2 Inhibitors Prevent Some Heart Failure Hospitalizations

Topics

Reviewing Author